Amgen Can't Halt Sandoz's Biosimilar Launch Ahead Of Appeal
A California federal judge on Wednesday denied a bid by Amgen Inc. to prevent Sandoz Inc. from launching the first copycat biologic drug approved under the Affordable Care Act while the...To view the full article, register now.
Already a subscriber? Click here to view full article